|
Apr 18
|
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
|
|
Apr 18
|
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
|
|
Dec 8
|
$19 Billion in a Week: AbbVie Makes Two Big Bets
|
|
Dec 7
|
Bain Capital Banks Massive Return on Cerevel Deal
|
|
Dec 7
|
Stocks to Watch Thursday: AbbVie, AMD, GameStop, Cerevel, JetBlue
|
|
Dec 7
|
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
|
|
Dec 6
|
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion
|
|
Dec 6
|
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
|
|
Nov 29
|
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
|
|
Nov 8
|
Cerevel Therapeutics to Present at Upcoming Investor Conferences
|